News
Predictors and Rate of Anticoagulant Therapy Discontinuation in Patients with Atrial Fibrillation
With the worldwide increase in the prevalence of atrial fibrillation (AF), the use of anticoagulants (warfarin, DOACs – direct oral anticoagulants) to reduce the risk of ischemic stroke (iCMP) is also rising. However, continuous use is essential. An Australian study analyzed available national data to investigate the rate of therapy discontinuation for individual anticoagulants and the predictors of persistence on treatment.
Association Between Sartan Therapy and Lower Incidence of Epilepsy in Hypertensive Patients?
Arterial hypertension (AH) is one of the non-cerebral comorbidities of epilepsy, with the…
RETRO-TAS Study – Trifluridine/Tipiracil in Pretreated mCRC in Real-World Practice
How does trifluridine/tipiracil (FTD/TPI), which demonstrated efficacy in clinical trials in…
Study TACTIC – Efficacy and Safety of Trifluridine/Tipiracil in Pre-treated mCRC Patients in Real-world Practice
In the pivotal phase III RECOURSE randomized placebo-controlled study, therapy with…
Sotorasib in the Treatment of a Patient with NSCLC and DIC – A Case Report
Sotorasib is the first clinically used inhibitor of the KRAS oncogene with the G12C mutation. Its…
Incidence of Brain Metastases and Intracranial Activity of Sotorasib in Patients with NSCLC with G12C Mutation of the KRAS Oncogene
Sotorasib is the first targeted drug approved for the treatment of metastatic non-small cell lung…
“Customized Schizophrenia Treatment”: Benefits of Therapeutic Innovations in Inpatient and Outpatient Care Thanks to Gentler Antipsychotics
In the field of schizophrenia treatment, the possibility of significantly greater…
Angiodysplasia as a Serious Problem in Patients with von Willebrand Disease − Case Study
Bleeding into the gastrointestinal tract can become a very significant cause of morbidity and mortality...
Pharmacotherapy of Glaucoma in a Nutshell According to the Latest Recommendations of the European Glaucoma Society
The European Glaucoma Society published its latest, 5th version of recommendations for the treatment...
Model of Risk of Bleeding Associated with Physical Activity in Hemophiliacs with Factor and Non-Factor Treatment
In the treatment of hemophilia A, both FVIII concentrate replacement therapy and non-factor therapy…